Fimasartan/Amlodipine Combination Phase III

NCT02152306 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2015-07-27

No results posted yet for this study

Summary

The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan 60mg monotherapy.

Conditions

  • Essential Hypertension

Interventions

DRUG

Fimasartan and Amlodipine

DRUG

Fimasartan

Sponsors & Collaborators

  • Gachon University Gil Medical Center

    collaborator OTHER
  • The Catholic University of Korea

    collaborator OTHER
  • Kangbuk Samsung Hospital

    collaborator OTHER
  • Kyungpook National University Hospital

    collaborator OTHER
  • Keimyung University Dongsan Medical Center

    collaborator OTHER
  • Korea University Guro Hospital

    collaborator OTHER
  • Korea University Anam Hospital

    collaborator OTHER
  • DongGuk University

    collaborator OTHER
  • Dong-A University Hospital

    collaborator OTHER
  • Pusan National University Hospital

    collaborator OTHER
  • Seoul National University Bundang Hospital

    collaborator OTHER
  • Seoul National University Hospital

    collaborator OTHER
  • Asan Medical Center

    collaborator OTHER
  • Pusan National University Yangsan Hospital

    collaborator OTHER
  • Wonju Severance Christian Hospital

    collaborator OTHER
  • Gangnam Severance Hospital

    collaborator OTHER
  • Severance Hospital

    collaborator OTHER
  • Ulsan University Hospital

    collaborator OTHER
  • Inje University

    collaborator OTHER
  • Inje University Haeundae Paik Hospital

    collaborator OTHER
  • Chonnam National University Hospital

    collaborator OTHER
  • Jeju National University Hospital

    collaborator OTHER
  • Chungnam National University

    collaborator OTHER
  • Hanyang University Seoul Hospital

    collaborator OTHER
  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Cheol Ho Kim, Ph.D. · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-03-31
Completion
2015-07-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02152306 on ClinicalTrials.gov